Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing

Galectin Therapeutics Inc. (NASDAQ: GALT) recently disclosed the outcomes of its 2024 Annual Meeting of Stockholders in a Form 8-K submission to the Securities and Exchange Commission.

During the meeting held on January 23, 2025, the stockholders of Galectin Therapeutics Inc. elected all nominated directors of the Company to serve until the subsequent annual meeting or until their replacements are chosen and qualified. Additionally, the stockholders ratified the appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the fiscal year concluding on December 31, 2024.

The detailed voting results from the 2023 Annual Meeting are as follows:

**Election of Directors:**

– Gilbert F. Amelio, Ph.D.: 18,236,198 votes for, 1,013,767 votes withheld, and 20,045,381 broker non-votes.
– Benjamin S. Carson, Sr., M.D.: 18,935,118 votes for, 314,847 votes withheld, and 20,045,381 broker non-votes.
– Kary Eldred: 18,919,225 votes for, 330,740 votes withheld, and 20,045,381 broker non-votes.
– Kevin D. Freeman: 18,617,186 votes for, 632,779 votes withheld, and 20,045,381 broker non-votes.
– Joel Lewis: 18,720,842 votes for, 529,123 votes withheld, and 20,045,381 broker non-votes.
– Gilbert S. Omenn, M.D., Ph.D.: 19,000,733 votes for, 249,232 votes withheld, and 20,045,381 broker non-votes.
– Marc Rubin, M.D.: 18,649,439 votes for, 600,526 votes withheld, and 20,045,381 broker non-votes.
– Elissa J. Schwartz, Ph.D.: 18,980,465 votes for, 269,500 votes withheld, and 20,045,381 broker non-votes.
– Harold H. Shlevin, Ph.D.: 18,719,597 votes for, 530,368 votes withheld, and 20,045,381 broker non-votes.
– Richard E. Uihlein, Chairman: 18,988,589 votes for, 261,376 votes withheld, and 20,045,381 broker non-votes.
– Richard A. Zordani: 18,993,681 votes for, 256,284 votes withheld, and 20,045,381 broker non-votes.

**Ratification of Cherry Bekaert LLP:**
– Votes For: 38,723,588
– Votes Against: 162,839
– Votes Abstain: 408,919

The Form 8-K filing also included the signature of Galectin Therapeutics Inc.’s Chief Financial Officer, Jack W. Callicutt, dated January 28, 2025, certifying the report on behalf of the company.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Galectin Therapeutics’s 8K filing here.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.